Recursion Pharmaceuticals Reports Q2 2026 Results; Genentech Options First Neuroscience Target

RECURSION PHARMACEUTICALS, INC.

2026-Q2 EPS reported -$0.47 revenue$14,143,000

Genentech exercised first Validated Target Option under neuroscience collaboration, advancing a previously unexplored target into early discovery program.
REC-4881 Phase 2 FAP data to be presented at CGA-IGC Presidential Plenary in November 2026; FDA discussions initiated for registrational path.
REC-7735 IND cleared; Phase 1/2 ZINNIA trial for PIK3CA H1047R-mutant solid tumors to start in 2H26.
Revenue was $7.7M in Q2 2026, down from $19.2M in Q2 2025; net loss improved to $131.0M from $171.9M.
Cash operating expense guidance reduced to <$375M for 2026; cash runway extends into early 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.